Johnson & Johnson (NYSE:JNJ) Shares Up 0.4%

Johnson & Johnson (NYSE:JNJ - Get Free Report) traded up 0.4% on Monday . The stock traded as high as $148.70 and last traded at $146.73. 1,276,009 shares traded hands during trading, a decline of 83% from the average session volume of 7,370,711 shares. The stock had previously closed at $146.16.

Analyst Ratings Changes

JNJ has been the topic of several recent analyst reports. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $215.00 price target on shares of Johnson & Johnson in a research report on Monday. HSBC raised Johnson & Johnson from a "hold" rating to a "buy" rating and boosted their price objective for the stock from $169.00 to $170.00 in a research note on Thursday, April 18th. Morgan Stanley cut their price target on Johnson & Johnson from $168.00 to $167.00 and set an "equal weight" rating for the company in a report on Wednesday, April 17th. StockNews.com raised shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Sunday. Finally, Bank of America dropped their target price on shares of Johnson & Johnson from $180.00 to $170.00 and set a "neutral" rating for the company in a research note on Wednesday, April 17th. Eight investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and an average price target of $174.07.

Johnson & Johnson Stock Performance

The company has a quick ratio of 0.94, a current ratio of 1.17 and a debt-to-equity ratio of 0.36. The stock has a market cap of $352.39 billion, a price-to-earnings ratio of 9.12, a PEG ratio of 2.43 and a beta of 0.52. The stock's fifty day moving average is $148.14 and its 200-day moving average is $154.05.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, topping the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The business had revenue of $21.38 billion for the quarter, compared to the consensus estimate of $21.39 billion. During the same quarter last year, the business posted $2.68 EPS. The firm's revenue was up 2.3% compared to the same quarter last year. On average, analysts forecast that Johnson & Johnson will post 10.62 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st were issued a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.39%. The ex-dividend date was Monday, May 20th. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.19. Johnson & Johnson's dividend payout ratio is 30.92%.

Institutional Trading of Johnson & Johnson

Institutional investors have recently modified their holdings of the company. 4J Wealth Management LLC increased its stake in Johnson & Johnson by 2.2% in the fourth quarter. 4J Wealth Management LLC now owns 2,835 shares of the company's stock worth $444,000 after purchasing an additional 62 shares during the period. My Personal CFO LLC grew its stake in Johnson & Johnson by 1.4% in the 4th quarter. My Personal CFO LLC now owns 4,550 shares of the company's stock worth $713,000 after acquiring an additional 62 shares in the last quarter. Eagle Strategies LLC raised its stake in shares of Johnson & Johnson by 1.8% during the fourth quarter. Eagle Strategies LLC now owns 3,589 shares of the company's stock valued at $563,000 after acquiring an additional 63 shares in the last quarter. Clearview Wealth Advisors LLC lifted its stake in Johnson & Johnson by 1.5% in the fourth quarter. Clearview Wealth Advisors LLC now owns 4,373 shares of the company's stock worth $685,000 after acquiring an additional 64 shares during the period. Finally, Brookmont Capital Management raised its stake in Johnson & Johnson by 0.4% in the fourth quarter. Brookmont Capital Management now owns 14,852 shares of the company's stock worth $2,328,000 after buying an additional 64 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.